Table 5.
Comparison of characteristics of study completers vs. drop-outs
| Dropouts after baseline (n=6) | Study completers (n=58) | Partial Completers* (n=20) | p-value completers vs. partial completers | Overall p-value | |
|---|---|---|---|---|---|
|
| |||||
| Age, mean (SD) | 47.6 (10.3) | 57.8 (14.7) | 52.9 (11.5) | 0.18 | 0.13 |
| Gender, Male | 6 (100%) | 42 (72%) | 13 (65%) | 0.53 | 0.24 |
| Select 1977 ACR gout classification criteria | |||||
| Hyperuricemia | 2 (33%) | 49 (85%) | 16 (80%) | 0.01 | |
| Joint subcortical cysts | 0 (0%) | 11 (19%) | 8 (40%) | 0.06 | |
| Urate crystals | 2 (33%) | 39 (67%) | 12 (60%) | 0.25 | |
| Race, n (%) | 0.75 | 0.82 | |||
| White | 4 (67%) | 40 (69%) | 13 (65%) | ||
| Black or African American | 1 (17%) | 15 (26%) | 5 (25%) | ||
| Other | 1 (17%) | 3 (5%) | 2 (10%) | ||
| #gout flares in the last year, mean (SD) | 3.5 (2.8) | 3.0 (2.6) | 6.9 (9.6) | 0.006 | 0.02 |
| Pt.-reported Last uric acid level at the first visit (mg/dl), mean (SD) | 9.0 (2.1) | 7.3 (3.2) | 7.8 (2.5) | 0.59 | 0.67 |
| BMI, mean (SD) | 29.1 (6.8) | 33.3 (9.6) | 34.5 (7.8) | 0.63 | 0.45 |
| Baseline HAQ-DI score, mean (SD) | 0.33 (0.57) | 0.55 (0.69) | 0.65 (0.73) | 0.57 | 0.59 |
| Residency Address in Alabama State, n (%) | 1 (17%) | 31 (53%) | 8 (40%) | 0.94 | 0.70 |
| Sangha Comorbidity Index Score, mean (SD) | 1.7 (1.5) | 3.8 (3.5) | 3.8 (3.9) | 0.99 | 0.36 |
| Ever Smoked | 1 (17%) | 23 (40%) | 10 (50%) | 0.41 | 0.34 |
| Currently smoke | 0 (0%) | 1 (4%) | 2 (20%) | 0.15 | 0.33 |
| Alcohol intake | |||||
| #days past week with drink | 1.7 (1.9) | 2.1 (3.4) | 1.3 (2.0) | 0.34 | 0.62 |
| #days past month with drink | 7.5 (9.3) | 7.3 (9.9) | 5.5 (8.6) | 0.46 | 0.75 |
| #drinks | 1.8 (1.0) | 1.4 (1.9) | 1.4 (1.9) | 0.94 | 0.87 |
| #days with >5 drinks | 0.8 (2.0) | 1.9 (5.2) | 1.3 (2.8) | 0.60 | 0.77 |
| Largest #drinks | 3.2 (4.5) | 2.2 (2.7) | 2.1 (3.1) | 0.90 | 0.75 |
| Doctor ever prescribed allopurinol, febuxostat or probenecid? | 6 (100%) | 46 (79%) | 15 (75%) | 0.68 | 0.40 |
| Prescribed allopurinol | 3 (50%) | 30 (52%) | 14 (70%) | 0.15 | 0.35 |
| Prescribed febuxostat | 1 (17%) | 1 (1%) | 0 (0%) | 0.55 | 0.05 |
| Current activity level | 0.48 | 0.81 | |||
| Sedentary | 2 (40%) | 14 (27%) | 8 (44%) | ||
| Low Active | 2 (40%) | 20 (39%) | 4 (22%) | ||
| Active | 1 (20%) | 16 (31%) | 5 (31%) | ||
| Very Active | 0 (0%) | 2 (4%) | 1 (4%) | ||
| Extremely Active | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Maximum pain in the last 24 hours | 2.8 (4.4) | 2.5 (3.0) | 2.5 (2.7) | 0.98 | 0.96 |
*
Partial completers: Completed at least one FU assessment, but not all three (3, 6- or 9-month)
Bold represents significant p-value < 0.05